Clinical Veterinarian
About the job
- Demonstrated expertise in avian medicine and surgery across multiple avian taxa.
- Strong working knowledge of laboratory animal medicine across rodent, small mammal, and avian species, research compliance, and IACUC regulatory frameworks.
- DEA licensure or ability to obtain it.
- Minimum 8 years of clinical veterinary experience, including meaningful time in avian medicine and laboratory animal medicine and hands-on experience with rodent and small mammal colonies.
- Demonstrated expertise in advanced anesthesia and surgical techniques in avian and research animal species.
- Provide comprehensive medical care across a diverse portfolio, particularly avian species, rodent colonies, and small mammal research animals.
- Perform physical examinations, diagnostic evaluations, and therapeutic interventions appropriate to avian and laboratory animal physiology.
- Develop case management plans for acute, chronic, and emergent conditions across taxa.
- Lead emergency and critical care response as needed, including field-based situations.
- Maintain accurate and compliant medical records within established record-keeping systems.
- Develop and oversee preventative medicine programs and whole-population health strategies, including colony health monitoring and sentinel programs.
- Provide medical oversight for rodent and small mammal colonies, including health surveillance, colony management, and genetic integrity support in coordination with research teams.
- Design and implement anesthetic protocols for avian species and research animals in hospital and field environments, including avian-specific inhalant and injectable protocols.
- Perform and oversee sedation, induction, monitoring, and recovery with attention to avian patients' unique physiologic demands.
- Operate and maintain modern anesthesia delivery and physiologic monitoring systems.
- Perform surgical procedures appropriate to program needs, including avian soft tissue procedures and research-related interventions.
- Establish anesthetic safety guidelines, drug formularies, and controlled substance management systems.
- Develop contingency protocols for complex or high-risk procedures.
- Design and implement clinical standard operating procedures for preventative medicine and colony health programs, quarantine, biosecurity and barrier housing standards, avian-specific anesthesia and surgical standards, controlled drug management, emergency response, and necropsy and pathology workflows.
- Establish pharmaceutical inventory systems and Drug Enforcement Administration-compliant tracking protocols.
- Advise on veterinary hospital and clinical facility design, including IACUC-compliant research animal housing, avian holding areas, and equipment selection.
- Support construction planning and activation of new animal facilities.
- Create scalable veterinary infrastructure to support program growth and species expansion.
- Lead implementation of quarantine protocols and health certification processes, including avian import/export health requirements.
- Oversee IACUC protocol development, amendments, and regulatory submissions in coordination with research teams.
- Ensure compliance with USDA APHIS, IACUC, DEA, and applicable federal and state regulations governing research animals and avian species.
- Develop and monitor biosecurity and zoonotic disease prevention protocols, including avian influenza preparedness and biosafety tier management.
- Partner with animal care teams on welfare assessments and behavioral health considerations.
- Support necropsy procedures and diagnostic sample management.
- Partner closely with the Chief Animal Officer on strategic planning and clinical priorities.
- Collaborate with animal husbandry, research, genetics, and facilities teams.
- Serve as the primary veterinary liaison for IACUC oversight and research compliance.
- Coordinate with external veterinary specialists and consultants as required.
- Contribute veterinary expertise to research initiatives requiring anesthesia, sampling, or surgical intervention.
- Help establish clinical best practices that align with conservation and research objectives.
- Be available for regular coverage during all hours, including weekends and holidays.
- Develop and implement emergency preparedness protocols.
- Support veterinary interventions in large-acreage and field environments.
- Lead clinical oversight during immobilizations and remote procedures.
- Board certification in Avian Practice (ABVP) or Laboratory Animal Medicine (ACLAM), or advanced training in either specialty.
- Experience supporting novel, emerging, or complex species programs.
- Experience standing up or scaling a veterinary program from early-stage operations.
- Familiarity with ratite, psittacine, passerine, or other specialized avian groups relevant to conservation programs.
- Experience with avian reproductive medicine, including artificial insemination and egg management protocols.
About the company
Colossal develops gene editing approaches to revive extinct or endangered species and restore ecological balance. It collects viable DNA samples and edits genes to rebuild traits of lost megafauna, with Woolly Mammoth as a leading project. Its technology translates into practical applications for species recovery and conservation, aiming to kickstart biodiversity and support the biology economy. Distinctive aspects include a focus on de-extinction tied to ecological restoration, leadership from Ben Lamm and George Church, and a strategy that links scientific capability with real-world ecological and economic benefits. The company’s goal is to reawaken lost wilds to help ecosystems recover and allow humanity to coexist with a healthier planet.
Company Size
51-200
Company Stage
Series C
Total Funding
$625M
Headquarters
Dallas, Texas
Founded
2021
Get referred to Colossal
See people who can refer or advise you
Simplify's Take
What believers are saying
- June 2026 USFWS agreement covers 2,300 ESA species and opens federal sampling.
- August 2026 Paw Patrol campaign expands consumer reach and conservation recruitment.
- 2026 publications and mammoth-cell edits validate the platform's scientific throughput.
What critics are saying
- Critics call dire wolves gray-wolf hybrids; that credibility gap threatens future fundraising.
- Elephant surrogacy, cloned embryos, and artificial eggs face welfare, failure, and regulatory backlash.
- A mammoth accident or habitat mismatch would trigger an existential de-extinction collapse.
What makes Colossal unique
- Colossal combines de-extinction branding with conservation biobanks and cloning infrastructure.
- Ben Lamm and George Church pair celebrity fundraising with multiplex CRISPR credibility.
- BioVault partnerships with U.S. Fish and Wildlife and Dubai create global specimen access.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Spending Account/Flexible Spending Account
401(k) Company Match
Paid Parental Leave
Education Reimbursement
Growth & Insights and Company News
6 month growth
-8%1 year growth
1%2 year growth
0%Colossal Biosciences has launched GenoMorph, an AI platform that helps identify genes to edit when bringing back extinct species with little genetic data. The company is using it in its dodo project, where it has just one dodo genome, against 100 for its woolly mammoth work. GenoMorph combines developmental data from chickens, quail, ducks, and pigeons with genetic information and 3D skull measurements from more than 70 bird species. It has found about 2,300 promising editing targets for the dodo's skull and face, which the company can now test in the lab. Colossal also said its Nicobar pigeon colony, the dodo's closest living relative, now has 36 birds. It has created the cells that become eggs and sperm. XPRIZE founder and Colossal investor Peter Diamandis announced a new VC firm, NeoGenesis Capital, to back companies using Colossal's platform.
Colossal Biosciences, a startup working to revive extinct species, has produced three genetically engineered dire wolf pups and is working on the woolly mammoth. Chief executive officer Ben Lamm told CNBC the company aims for a mammoth birth in the 2030s. Colossal used AI models to rebuild the dire wolf genome from ancient DNA, then edited gray wolf cells to create embryos. Domestic dogs served as surrogate mothers. Skeptics say the pups are modified gray wolves; Lamm called that a "semantic argument." Lamm says the work could advance gene therapies, conservation, and climate efforts. Colossal announced a $200 million Series C round in July, led by TWG Global, at a $10.2 billion valuation. It has raised more than $435 million in total.
Real-life Mammoths by the 2030s? Scientists plan to bring back the Ice Age giant with AI. Could woolly mammoths return by the 2030s? Discover how scientists are using AI, gene editing and reproductive technology to create mammoth-like elephants. September 27, 2026 / 13:43 IST Scientists are using AI and gene editing to develop a mammoth-like elephant by 2030. (Image: Canva) * Company aims to create a mammoth-like elephant. * AI to help identify genetic traits for cold adaptation. * Project faces challenges; timeline shifted to 2030s. Did our AI summary help? The woolly mammoth disappeared thousands of years ago. Now, a biotechnology company is attempting to recreate some of its defining characteristics in a living elephant. Colossal Biosciences is developing a cold-adapted, mammoth-like elephant by introducing selected genetic traits associated with the extinct species. The project has attracted attention for its ambition to bring an Ice Age animal back into the modern world. However, the goal is not to produce an exact copy of a woolly mammoth. Why are scientists trying to bring back woolly mammoths? Woolly mammoths once roamed cold environments across parts of the Northern Hemisphere. Their thick coats, insulating fat and other adaptations helped them survive harsh conditions. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated! Watch. Must listen. * On Saturdays Find the best of Al News in one place, specially curated for you every weekend. * Daily-Weekdays Stay on top of the latest tech trends and biggest startup news.
AI de-extinction revolution: how a billion-dollar startup is engineering nature's comeback at TechCrunch Disrupt 2026. Tl;dr. * Colossal Biosciences, the $10.2 billion de-extinction startup founded by Ben Lamm and George Church, will take center stage at TechCrunch Disrupt 2026 to detail how AI-driven genomics has moved species revival from theory to live animals. * After creating woolly mice and dire wolf pups in 2025, the company is now using AI models for ancient DNA reconstruction, multiplex gene editing, and synthetic surrogacy to target the woolly mammoth, dodo, and thylacine within the next few years. * The breakthrough raises massive questions for biodiversity, biotech investment, and conservation ethics, positioning de-extinction as both a climate tool and a commercial platform for genetic engineering. From science fiction to lab reality. For decades, de-extinction lived in the realm of Jurassic Park fantasies. That changed this past year. Colossal Biosciences, the Dallas-based startup now valued at over $10 billion after its $200 million Series C in January 2025, has produced living, breathing proof points that extinct traits can be re-engineered into modern animals. In March 2025, the company unveiled the woolly mouse, a mouse engineered with mammoth-like hair and cold-adapted fat metabolism. Just weeks later in April, it revealed Romulus, Remus, and Khaleesi - three dire wolf pups carrying revived genes from the extinct Aenocyon dirus, an animal that vanished more than 10,000 years ago. The announcements went viral globally and instantly turned Colossal's co-founder and CEO Ben Lamm into biotech's most unconventional celebrity founder. Lamm, a serial entrepreneur known for gaming and AI startups before pivoting to synthetic biology, is slated to speak at TechCrunch Disrupt 2026 in San Francisco this October. The previewed session promises a candid look at how the company scaled from a moonshot idea in 2021 to a sprawling genetic engineering platform with more than 170 scientists and labs across Texas, Massachusetts, and Australia. The unconventional founder leading the charge. Ben Lamm doesn't look or talk like a typical biotech CEO. No lab coat, no cautious pharma-speak. His pitch is pure Silicon Valley disruption: make extinction reversible, build the software stack for life itself, and spin out billion-dollar companies along the way. Backed by investors including In-Q-Tel, Breyer Capital, WestRiver Group, and actor Chris Hemsworth, Colossal has raised over $615 million to date. Lamm's strategy has been to treat de-extinction like a tech platform problem, not just a conservation project. At Disrupt 2026, he is expected to discuss fundraising at massive scale during a biotech downturn, managing public hype versus scientific timelines, and why he believes bold, story-driven science is essential to attract top AI and CRISPR talent. Joining him in spirit, if not on stage, is co-founder George Church, the Harvard and MIT geneticist whose lab pioneered multiplex CRISPR editing. Together, the duo paired Church's academic depth with Lamm's aggressive commercial execution. How AI cracked the ancient DNA code. The real revolution isn't just CRISPR - it's AI. Ancient DNA is fragmented, degraded, and incomplete after thousands of years in permafrost or cave fossils. Reconstructing a full woolly mammoth or dodo genome by hand would take decades. Colossal's computational biology team now uses deep learning models trained on modern elephant, wolf, pigeon, and marsupial genomes to predict and fill in missing ancient sequences, identify functional gene variants linked to cold tolerance, skull shape, coat color, and metabolism, and model off-target effects before any cell is edited. The company has built proprietary pipelines for paleogenome assembly, AI-guided guide-RNA design for multiplex editing - editing dozens of genes at once - and embryo modeling to reduce reliance on animal surrogates. The same AI stack is now being commercialized for human healthcare, agriculture, and conservation through spinouts like Breaking, focused on plastic degradation, and Colossal's dire wolf cloning tech adapted for endangered red wolves. From dire wolves to mammoths, dodos, and thylacines. So where does the science actually stand ahead of Disrupt 2026? Dire Wolf: Colossal's most advanced program. Using gray wolf cells edited with 20 dire wolf traits related to size, musculature, and coat, then cloned via somatic cell nuclear transfer, the three live pups are now over a year old and thriving in a 2,000-acre preserve. Woolly Mammoth: The flagship goal. The team has edited over 25 mammoth-specific genes into Asian elephant cells and demonstrated successful elephant iPSC generation, a major hurdle cleared in 2025. First mammoth calves are still targeted for 2028. Dodo and Thylacine: The avian genomics program completed a high-quality dodo reference genome using DNA from a 17th-century specimen, while the thylacine program in Melbourne has produced edited fat-tailed dunnart cells, a marsupial proxy. Both are positioned as tests for bird and marsupial reproductive engineering. Moas and others from Colossal's expanded extinction list, plus partnerships with Indigenous groups and rewilding projects in North America, Mauritius, and Tasmania, signal a shift from lab demos to field deployment. What it means for biodiversity and biotech. Supporters argue de-extinction could be a powerful conservation tool. Reintroducing mammoth-like grazers to the Arctic could slow permafrost thaw, rewilded dire wolf proxies could restore predator balance, and the gene-editing tools developed could save critically endangered species like the northern white rhino, vaquita, and pink pigeon. Critics warn of ecological risks, animal welfare concerns around surrogacy and cloning, and the moral hazard of suggesting extinction is fixable. Conservation biologists also question whether hundreds of millions should fund revived icons while thousands of living species face imminent loss. Lamm has countered that it's not either-or. Colossal says it has donated tech and funding to traditional conservation and that its biobanking and cloning advances already helped produce two cloned red wolf pups in 2025 using a less-invasive blood-cloning technique. The road to Disrupt 2026 and beyond. TechCrunch Disrupt 2026 comes at an inflection point. With a potential IPO or large private raise rumored, increasing regulatory scrutiny around engineered animals, and growing competition from startups like Loyal, Ginkgo Bioworks, and Chinese BGI-affiliated labs entering paleogenomics, all eyes will be on Lamm's live Q&A. Expect tough questions: When will Androguider see a baby mammoth? Who owns a revived species? How do you rewild an animal with no herd, no culture, and a changed climate? And can AI-designed genomes ever truly recreate an extinct mind, not just its body? Whatever the answers, one thing is clear heading into October: AI-powered genetic engineering has turned de-extinction from science fiction into a funded, staffed, and rapidly advancing industry. Nature's comeback is no longer a question of if, but how, when, and at what cost. AndroGuider Team Articles written by the AndroGuider team. Androguider try to make them thorough and informational while being easy to read.
Colossal Biosciences teams up with Paw Patrol to inspire the next generation of protectors. BY Colossal Biosciences Colossal Biosciences has teamed up with Paramount and Spin Master on a new conservation campaign built around the Paw Patrol pups, The Hollywood Reporter exclusively reported. It tells children that endangered animals in the real world can't count on a Paw Patrol to save them, and that the threats they face most often come from disease and from humans. At its center is a call-to-action video made with Godzilla: King of the Monsters writer-director Michael Dougherty and Carter Young, the voice of firedog Marshall, that casts kids as the next generation of protectors and urges them to "become a real-life Paw Patrol for our planet." The effort arrives alongside Paw Patrol: The Dino Movie, which strands the pups on an island full of dinosaurs. The campaign also highlights Colossal's broader efforts as a de-extinction company working to bring back the woolly mammoth. As the article notes, its conservation efforts include the red wolf, the most endangered of all wolf species, with just 14 surviving in the wild. Colossal has also used AI-enabled bioacoustic sensors to decode wolf howls, and is currently partnering with indigenous tribes and others on more than 25 conservation projects that combine AI and biotechnology, including work to help save rhinos and amphibians. This story is based on original reporting by Tony Maglio for The Hollywood Reporter. Read the full feature on The Hollywood Reporter